The estimated Net Worth of Franklin M Berger is at least $2.16 Million dollars as of 16 June 2024. Mr. Berger owns over 33,150 units of Kezar Life Sciences Inc stock worth over $470,672 and over the last 20 years he sold KZR stock worth over $1,588,083. In addition, he makes $97,434 as Independent Director at Kezar Life Sciences Inc.
Franklin has made over 36 trades of the Kezar Life Sciences Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 33,150 units of KZR stock worth $19,227 on 16 June 2024.
The largest trade he's ever made was selling 272,840 units of Kezar Life Sciences Inc stock on 14 December 2022 worth over $728,483. On average, Franklin trades about 15,100 units every 47 days since 2004. As of 16 June 2024 he still owns at least 811,503 units of Kezar Life Sciences Inc stock.
You can see the complete history of Mr. Berger stock trades at the bottom of the page.
Franklin M. Berger, CFA., is Independent Director of the Company. Mr. Berger worked at Sectoral Asset Management as a founder of the small-cap focused NEMO Fund from January 2007 through June 2008. Prior to that, he served at J.P. Morgan Securities, most recently as Managing Director, Equity Research and Senior Biotechnology Analyst and served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger has served as a member of the board of directors of Five Prime Therapeutics, Inc. since October 2014, Tocagen Inc. since October 2014, Bellus Health, Inc. since May 2010, ESSA Pharma, Inc. since March 2015, and Proteostasis Therapeutics, Inc. since February 2016. Mr. Berger previously served as a member of the board of directors BioTime, Inc., Seattle Genetics, Inc. and Immune Design Corp., each publicly held biotechnology companies.
As the Independent Director of Kezar Life Sciences Inc, the total compensation of Franklin Berger at Kezar Life Sciences Inc is $97,434. There are 9 executives at Kezar Life Sciences Inc getting paid more, with John Fowler having the highest compensation of $3,532,020.
Franklin Berger is 70, he's been the Independent Director of Kezar Life Sciences Inc since 2016. There are no older and 14 younger executives at Kezar Life Sciences Inc.
Franklin's mailing address filed with the SEC is 225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110.
Over the last 6 years, insiders at Kezar Life Sciences Inc have traded over $3,836,099 worth of Kezar Life Sciences Inc stock and bought 6,372,267 units worth $30,891,130 . The most active insiders traders include Venture Investments Ltd Mor..., Asset Management, Lp Chen B..., and Franklin M Berger. On average, Kezar Life Sciences Inc executives and independent directors trade stock every 49 days with the average trade being worth of $91,954. The most recent stock trade was executed by Mark C. Schiller on 2 July 2024, trading 6,688 units of KZR stock currently worth $3,879.
kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.
Kezar Life Sciences Inc executives and other stock owners filed with the SEC include: